Product Pipeline

Microbiome Therapeutics Pipeline
Microbiome Pharmaceuticals Discovery
Clinical programs

Ongoing Phase 2 with MH002 in Ulcerative Colitis and the orphan indication Pouchitis.

Microbiome Pharmaceuticals Preclinical
Preclinical programs

Parkinson’s disease.
Metabolic diseases (partnered).

Microbiome Pharmaceuticals Discovery Programs
Discovery programs

Ongoing program in spondylarthritis and autoimmune conditions.



Effective live biotherapeutics

Designed for efficacy, developed for synergy, produced as one.

Contact us